A photo of Punam Malik.

Punam Malik, MD

  • Director, Cincinnati Comprehensive Sickle Cell Center
  • Program Leader, Hematology and Gene Therapy Program
  • Marjory J. Johnson Chair, Gene and Cell Therapy
  • Professor, UC Department of Pediatrics
appointment iconMake An Appointment
MyChart Icon
Existing PatientsMyChart Scheduling
AppointmentsCall Us to ScheduleAppointments1-513-636-3200

About

MBBS: University of Delhi, New Delhi, India, 1985.

MD: University of Delhi, New Delhi, India, 1989.

MS: University of Maryland, Baltimore, MD, 1991.

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

Services and Specialties

Research Areas

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data Hub. Niss, O; Fenchel, M; Kingsley, E; Latham, TS; Malik, P; Quinn, CT. Blood. 2024; 144:2312.

Blockade of Angiotensin II Signaling Ameliorates Cardiac Fibrosis and Improves Diastolic Dysfunction in Mice with Sickle Cell Anemia. Little, K; Zhu, Z; Gbotosho, O; Malik, P. Blood. 2024; 144:2480.

Splenic Ossification in Sickle Cell Anemia Mice. Chi, M; Vandenheuvel, K; Malik, P. Blood. 2024; 144:5283.

A Novel Mouse Model of Hemoglobin-SC Disease: Bridging the Knowledge Gap in Sickle Cell Disease. Setayesh, T; Chi, M; Oestreicher, Z; Sakabe, M; Mei, X; Vandenheuvel, K; Townes, TM; Hu, Y; Malik, P. Blood. 2024; 144:620.

Longitudinal Assessment of Myocardial Fibrosis in Sickle Cell Disease. Niss, O; Morin, C; Lang, SM; Alsaied, T; Tasset, M; Malik, P; Quinn, CT. Blood. 2024; 144:799.

Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies. Shadid, M; Shrestha, A; Malik, P. PloS one. 2024; 19:e0306719.

NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model. Pastura, P; McDaniel, CG; Alharbi, S; Fox, D; Coleman, B; Malik, P; Adams, DM; Le Cras, TD. Pediatric Blood and Cancer. 2024; 71:e31032.

CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model. Neidemire-Colley, L; Khanal, S; Braunreiter, KM; Gao, Y; Kumar, R; Snyder, KJ; Weber, MA; Surana, S; Toirov, O; Karunasiri, M; Kararoudi, MN; Choe, HK; Garzon, R; Ranganathan, P. Blood Advances. 2024; 8:947-958.

Generation of a tyrosine hydroxylase-2A-Cre knockin non-human primate model by homology-directed-repair-biased CRISPR genome editing. Yoshimatsu, S; Okahara, J; Yoshie, J; Igarashi, Y; Nakajima, R; Sanosaka, T; Qian, E; Sato, T; Kobayashi, H; Morimoto, S; Kishi, N; Pillis, DM; Malik, P; Noce, T; Okano, H. Cell Reports: Methods. 2023; 3:100590.

Strategies for precise gene edits in mammalian cells. Fichter, KM; Setayesh, T; Malik, P. Molecular Therapy-Nucleic Acids. 2023; 32:536-552.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating
Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers